Learn, Analyse & Invest
only with

+91

Download Orca

To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Onesource Specialty Pharma Ltd.

Onesource Specialty

₹ 0.00

0.00 (0.00)%

NSE

BSE

Healthcare

Small-cap - With a market cap of ₹199.39 Cr.

EX-Date	Purpose
29 01 2025	Quarterly Results
05 05 2025	Audited Results
04 08 2025	Quarterly Results
11 11 2025	Quarterly Results
23 01 2026	Quarterly Results

News

29-APR-2026

Onesource Specialty’s partner gets Health Canada nod for Generic Semaglutide Injection

The company serves as the CDMO partner on this program, providing scale-up and manufacturing support

10:00 AM

29-APR-2026

OneSource Specialty Pharma secures EU GMP certificate for SPD facility

The certificate covers sterile products, including aseptically prepared small volume liquids, secondary packing and quality control testing

09:39 AM

21-APR-2026

OneSource Specialty’s partner gets tentative USFDA nod for generic version of Ozempic

The collaboration is designed to ensure reliable commercial supply from the company’s US-FDA approved flagship site in Bangalore

11:20 AM

18-APR-2026

OneSource Specialty Pharma gets EU-GMP renewal for Bengaluru facility

Unit II is a flagship integrated biologics drug-substance and drug-product manufacturing site with capabilities in drug-device combinations and sterile injectable products

11:02 AM

11-FEB-2026

OneSource Specialty Pharma secures SFDA approval for generic Ozempic

The approval represents an important entry for OneSource Specialty Pharma into the Kingdom of Saudi Arabia

10:50 AM

11-JUN-2025

OneSource partners with Xbrane Biopharma AB for biosimilars manufacturing

As part of the agreement, Xbrane will tech transfer its select products to the company’s state-of-the-art integrated drug substance and drug product facility in Bangalore, India

05:43 PM

10-JUN-2025

OneSource Specialty Pharma’s Bangalore facility gets VAI classification from USFDA

Following an inspection of the company’s flagship facility from March 20 to March 28, 2025, the USFDA issued a Form 483 with four observations

11:14 AM

10-APR-2025

OneSource Specialty Pharma gets GMP certification for flagship unit 2 facility

The company has received GMP certification from ANVISA

11:44 AM

31-MAR-2025

OneSource Specialty Pharma gets four observations from USFDA for Bangalore facility

The inspection was conducted at company’s Unit 2 Facility located in Bangalore

02:58 PM

29-JAN-2025

OneSource Specialty gets EIR with VAI status for BLD facility in Bangalore

The report follows an inspection of the facility, conducted from November 14 - 22, 2024

09:29 AM